Lincoln Pharma has reported net profit of Rs 15.01 crore for the Q1FY23 as against net profit of Rs 11.10 crore in Q4FY22, growth of 35.2 per cent Q-o-Q. Total income for the quarter ended June 2022 was reported at Rs 129.97 crore, higher 24.4 per cent Q-o-Q over total income of Rs 104.43 crore in Q4FY22. EBITDA for Q1FY23 was reported at Rs 23.41 crore as compared to EBITDA of Rs 19.32 crore in Q4FY22 – growth of 21.14 per cent Q-o-Q. EPS for Q1FY23 was at Rs 7.49 per share. Exports in Q1FY23 was reported at Rs 66.08 crore, a statement from the company saidv.
It also mentioned that during FY22, the company launched 14 products in the domestic market and filled 110 dossiers in the export market. In FY23, the company will look to consolidate its position in the lifestyle and chronic segments.
In September 2021, the company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products. The company has invested Rs 30 crore in the Cephalosporin plant – including acquisition and subsequent capacity expansion using internal source of funds. The plant is expected to start commercial production in the current fiscal and is expected to contribute sales of around Rs 150 crore in the next three years. The plant will cater to all the Cephalosporin products i.e. tablet, capsule, dry syrup and injectable, added the statement.
It further stated that the company has reported a robust financial and operational performance during the last decade (FY12 to FY22) maintaining strong CAGR 30 per cent in net profits, 20 per cent in EBITDA and 10 per cent in revenue, the statement concluded.
Great work. Keep it up!!!!